A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer.
Zhao SG, Sperger JM, Schehr JL, McKay RR, Emamekhoo H, Singh A, Schultz ZD, Bade RM, Stahlfeld CN, Gilsdorf CS, Hernandez CI, Wolfe SK, Mayberry RD, Krause HM, Bootsma M, Helzer KT, Rydzewski N, Bakhtiar H, Shi Y, Blitzer G, Kyriakopoulos CE, Kosoff D, Wei XX, Floberg J, Sethakorn N, Sharifi M, Harari PM, Huang W, Beltran H, Choueiri TK, Scher HI, Rathkopf DE, Halabi S, Armstrong AJ, Beebe DJ, Yu M, Sundling KE, Taplin ME, Lang JM.
Zhao SG, et al. Among authors: rathkopf de.
J Clin Invest. 2022 Nov 1;132(21):e161858. doi: 10.1172/JCI161858.
J Clin Invest. 2022.
PMID: 36317634
Free PMC article.